FDA partially halts Nurix Therapeutics’ cancer trial as it improves manufacturing process
The FDA is pausing patient enrollment and screening for Nurix Therapeutics’ Phase I clinical trial for a potential drug to treat B-cell malignancies in cancer patients.
The agency is halting the trial after Nurix told the FDA it is improving the manufacturing process of the potential drug, known as NX-2127, which is a degrader of BTK and IMiD neosubstrates.
Nurix is in communication with the FDA to “introduce the improved NX-2127 manufacturing process and drug product into our clinical development plan,” CEO Arthur Sands said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.